<DOC>
	<DOC>NCT00640562</DOC>
	<brief_summary>Aim of the study is to assess if the new compound Seroquel XR™ is non-inferior to Risperidone, considered as the reference drug for the treatment of depressive symptoms of schizophrenia. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.</brief_summary>
	<brief_title>Quetiapine Extended Release Depression Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Provision of written informed consent Patients who satisfy the criteria for diagnosis of schizophrenia or schizoaffective disorder according to DSMIVTR Baseline depressive symptoms, assessed by means of HAMD (21item) score ≥20, and HAMD item 1 score ≥2 Any DSMIV Axis I disorder other than schizophrenia and schizoaffective disorder Patients treated with depot antipsychotic medications within 1 dosing interval before day 0; patients treated with other AP oral medications during the trial except for the switch period Use of Clozapine within 28 days prior to enrollment or Clozapine non responders Any significant clinical disorder that, in the opinion of the investigator, made the subject unsuitable to be given treatment with an investigational drug An absolute neutrophil count (ANC) of ≤1.5 x 109 per liter Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Depression</keyword>
	<keyword>Quetiapine</keyword>
</DOC>